Insider · CIK 0001573722
Kenneth Hoberman
Files at TGTX (TG THERAPEUTICS, INC.), NVCT (Nuvectis Pharma, Inc.). First filing -, latest -.
Kenneth Hoberman files SEC Form 4 as director at TGTX (TG THERAPEUTICS, INC.), and also at NVCT (Nuvectis Pharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Kenneth Hoberman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | TGTX TG THERAPEUTICS, INC. | AGrant or award Common Stock | +14,718 | $0.00 | $0 | 279,653 | Jun 16, 2025 |
| Jun 12, 2025 | NVCT Nuvectis Pharma, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 133,140 | Jun 12, 2025 |
Questions about Kenneth Hoberman
Answered from the filings on this page, as of the latest one.
Is Kenneth Hoberman buying or selling?
Kenneth Hoberman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Kenneth Hoberman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kenneth Hoberman has 0.
Where does Kenneth Hoberman file Form 4?
Kenneth Hoberman has filed Form 4 at TGTX (TG THERAPEUTICS, INC.); NVCT (Nuvectis Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.